{"id":745395,"date":"2016-04-13T00:00:00","date_gmt":"2016-04-13T00:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/"},"modified":"2025-11-07T01:25:54","modified_gmt":"2025-11-07T06:25:54","slug":"mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/","title":{"rendered":"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial"},"content":{"rendered":"<p class=\"bwalignc\">       Results From C-EDGE Head-to-Head Study in Patients with        Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The        International Liver Congress\u2122 2016     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the presentation of results from <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02358044&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=C-EDGE+Head-to-Head&amp;index=1&amp;md5=a679483ac5c064603beb8b15c361357c\" rel=\"nofollow\"><i>C-EDGE<br \/>\n      Head-to-Head<\/i><\/a><i>, <\/i>the company\u2019s comparative, Phase 3,<br \/>\n      open-label clinical trial evaluating the efficacy and safety of<br \/>\n      ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets versus a regimen<br \/>\n      of sofosbuvir 400mg tablets plus peginterferon and ribavirin<br \/>\n      (pegIFN\/RBV) in treatment-na\u00efve and pegIFN\/RBV treatment-experienced<br \/>\n      patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection<br \/>\n      (abstract #PS002). In this study, ZEPATIER demonstrated superiority on<br \/>\n      efficacy and safety endpoints compared to sofosbuvir plus pegIFN\/RBV,<br \/>\n      based on pre-specified analyses. In the full analysis set (FAS) (n=255),<br \/>\n      the efficacy endpoint of sustained virologic response (SVR) 12 weeks<br \/>\n      after the completion of therapy (SVR12, considered virologic cure) was<br \/>\n      achieved in 99 percent (128\/129) of patients receiving ZEPATIER for 12<br \/>\n      weeks versus 90 percent (114\/126) of patients receiving sofosbuvir plus<br \/>\n      pegIFN\/RBV for 12 weeks. The study\u2019s safety endpoint was the frequency<br \/>\n      of pre-specified (Tier 1) safety events focusing on tolerability,<br \/>\n      hematologic side effects, and liver-related laboratory abnormalities.<sup>1<\/sup><br \/>\n      ZEPATIER \u2013 Merck\u2019s once-daily, fixed-dose combination tablet indicated<br \/>\n      with or without RBV for the treatment of chronic HCV GT1 or GT4<br \/>\n      infection in adults \u2013 was approved by the U.S. Food and Drug<br \/>\n      Administration (FDA) on Jan. 28, 2016, based in part on prior studies<br \/>\n      from the Phase 3 program. The results of <i>C-EDGE Head-to-Head<\/i> will<br \/>\n      be featured today in the official press program at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Filc-congress.eu%2F&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=The+International+Liver+Congress%E2%84%A2+2016&amp;index=2&amp;md5=30135291bf917d378ef4d7a1e5e91ad5\" rel=\"nofollow\">The<br \/>\n      International Liver Congress\u2122 2016<\/a>.\n    <\/p>\n<p>\n      \u201cOverall in this study, the elbasvir and grazoprevir regimen showed<br \/>\n      superior SVR rates and improvement on pre-specified safety endpoints<br \/>\n      compared to the sofosbuvir plus peginterferon and ribavirin regimen in<br \/>\n      these genotype 1- or 4-infected patients,\u201d said Dr. Jan Sperl,<br \/>\n      Department of Hepatogastroenterology, Institute for Clinical and<br \/>\n      Experimental Health, Prague, Czech Republic and lead study investigator.<br \/>\n      \u201cSofosbuvir in combination with peginterferon and ribavirin continues to<br \/>\n      be a prescribed treatment regimen in many regions, and this comparative<br \/>\n      study versus combination treatment with elbasvir and grazoprevir<br \/>\n      provides interesting and important insights.\u201d\n    <\/p>\n<p>\n      <i>C-EDGE Head-to-Head <\/i>is a comparative Phase 3, randomized,<br \/>\n      open-label, parallel-group trial conducted at multiple sites in the<br \/>\n      European Union, Norway and Turkey, and was designed to evaluate the<br \/>\n      efficacy and safety of 12 weeks of ZEPATIER (elbasvir and grazoprevir)<br \/>\n      versus a 12 week treatment regimen of sofosbuvir plus pegIFN\/RBV. The<br \/>\n      trial enrolled treatment-na\u00efve and pegIFN\/RBV treatment-experienced<br \/>\n      patients, with or without cirrhosis, with chronic HCV GT1 or GT4<br \/>\n      infection. Investigators were to enroll only patients whom, in their<br \/>\n      opinion, were appropriate candidates for 12 weeks of pegIFN\/RBV-based<br \/>\n      therapy; this assessment included consideration of factors associated<br \/>\n      with lower response rates to interferon-based therapies (e.g., advanced<br \/>\n      fibrosis\/cirrhosis, high baseline viral concentrations, black race,<br \/>\n      IL28B non-CC genotype, or prior null-response to pegIFN\/RBV therapy).<br \/>\n      The study randomized 255 GT1- or GT4-infected patients to 12 weeks of<br \/>\n      treatment with either ZEPATIER (elbasvir and grazoprevir) 50mg\/100mg<br \/>\n      tablets (n=129) or sofosbuvir 400mg tablets plus pegIFN\/RBV (n=126).<br \/>\n      Overall, at baseline, 17 percent of patients had compensated cirrhosis;<br \/>\n      67 percent had HCV RNA greater than 800,000 IU\/mL; 99 percent were<br \/>\n      white; 78 percent had IL28B non-CC genotype; and approximately 25<br \/>\n      percent had failed prior treatment with pegIFN\/RBV (10% prior<br \/>\n      null-responders, 5% prior partial-responders, 10% prior relapsers).\n    <\/p>\n<p>\n      In the FAS (n=255), the efficacy analyses demonstrated superiority of<br \/>\n      ZEPATIER compared to sofosbuvir plus pegIFN\/RBV, as measured by SVR12.<sup><br \/>\n      2<\/sup> Higher SVR rates were observed among those receiving ZEPATIER<br \/>\n      (elbasvir and grazoprevir) in subgroups of patients who had previously<br \/>\n      experienced a non-response to pegIFN\/RBV therapy and in those with<br \/>\n      cirrhosis, higher baseline viral load, or IL28B non-CC genotype.<br \/>\n      Efficacy results for the overall population as well as those for<br \/>\n      selected subgroups are shown in Table 1. In the ZEPATIER group, one<br \/>\n      patient (1%) discontinued from the trial after completing treatment.<br \/>\n      There were no virologic failures in the ZEPATIER group. In the<br \/>\n      sofosbuvir plus pegIFN\/RBV group, virologic failure occurred in 11<br \/>\n      patients (9%) and one patient (1%) discontinued from the trial after the<br \/>\n      first week of treatment.\n    <\/p>\n<p>\n      <b>Table 1: Summary of Efficacy (SVR12) Findings in FAS, Overall and<br \/>\n      Selected Subgroups<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Population<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          <b>ZEPATIER<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=129)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignb bwalignc bwsinglebottom\">\n          <b>Sofosbuvir + PegIFN\/RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=126)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>All Patients<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          99% (128\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          90% (114\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Genotype<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          GT1a\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (18\/18)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (17\/17)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          GT1b\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          99% (104\/105)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          90% (94\/104)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          GT4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (6\/6)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          60% (3\/5)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Cirrhotic\/Non-cirrhotic<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          Non-cirrhotic\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          99% (106\/107)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93% (98\/105)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          Cirrhotic\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (22\/22)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          76% (16\/21)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Prior Treatment Experience<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          Treatment-na\u00efve\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          99% (99\/100)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          96% (87\/91)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          PegIFN\/RBV Null-response\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (11\/11)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          50% (7\/14)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          PegIFN\/RBV Partial-response\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (6\/6)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          88% (7\/8)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl3  bwvertalignm bwalignl bwsinglebottom\">\n          PegIFN\/RBV Relapse\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (12\/12)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          100% (13\/13)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The primary safety analysis compared the incidence of adverse events<br \/>\n      (AEs) of special relevance (Tier 1 AEs) between the ZEPATIER and<br \/>\n      sofosbuvir plus pegIFN\/RBV treatment groups. Additional AEs (Tier 2 AEs)<br \/>\n      also were recorded. Safety results are shown in Table 2. Overall, the<br \/>\n      incidence of Tier 1 AEs, including those commonly associated with pegIFN<br \/>\n      and\/or RBV such as hematological side effects of decreased hemoglobin<br \/>\n      and decreased neutrophil count, were lower in the ZEPATIER treatment<br \/>\n      group versus the sofosbuvir plus pegIFN\/RBV treatment group. In the<br \/>\n      ZEPATIER (elbasvir and grazoprevir) treatment group, headache was the<br \/>\n      only AE reported at a frequency of greater than 10 percent. In the<br \/>\n      sofosbuvir plus pegIFN\/RBV treatment group, AEs reported in greater than<br \/>\n      10 percent of patients were pyrexia, headache, fatigue, asthenia,<br \/>\n      influenza-like illness, chills, myalgia, decreased appetite, anemia,<br \/>\n      nausea and cough. No grade three or four abnormalities of alanine<br \/>\n      aminotransferase (ALT), aspartate aminotransferase (AST) or hemoglobin<br \/>\n      were observed in the ZEPATIER group. In the sofosbuvir plus pegIFN\/RBV<br \/>\n      group, one patient had a grade three ALT abnormality and five patients<br \/>\n      had grade three or four hemoglobin reduction.\n    <\/p>\n<p>\n      <b>Table 2: Summary of Safety Findings<\/b>\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>ZEPATIER<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=129)<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n          <b>Sofosbuvir + PegIFN\/RBV<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(n=126)<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Tier 1 Adverse Events<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1% (1\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          28% (35\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Serious Drug Related Adverse Events (DRAEs)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          2% (3\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Discontinuations due to DRAE\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1% (1\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Neutrophil Count &lt;0.75 x 10<sup>9<\/sup>\/L\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13% (16\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Hemoglobin &lt;10 g\/dL\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1% (1\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          14% (18\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Tier 2 Adverse Events<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          52% (67\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93% (117\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          One or more adverse events\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          52% (67\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          93% (117\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          One or more drug related adverse events\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          25% (32\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          90% (114\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Serious adverse events\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1% (1\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4% (5\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          <b>Other Safety Events<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          ALT Grade 3 or 4: &gt;5.1 x ULN (IU\/L)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          1% (1\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          AST Grade 3 or 4: &gt;5.1 xULN (IU\/L)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\">\n          Hemoglobin Grade 3 or 4: &lt;9.0 (mg\/dL)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0% (0\/129)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          4% (5\/126)\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      \u201cTreatment regimens containing peginterferon and ribavirin are<br \/>\n      associated with certain serious side effects,\u201d said Dr. Jan Gerstoft,<br \/>\n      Clinic for Infectious Diseases and Rheumatology, Copenhagen, Denmark.<br \/>\n      \u201cThis study provides evidence for the clinical potential of elbasvir and<br \/>\n      grazoprevir in chronic HCV genotype 1- or 4-infection as compared with a<br \/>\n      regimen containing peginterferon and ribavirin along with sofosbuvir.\u201d\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER (elbasvir and grazoprevir)<\/b>\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3) inhibitors<br \/>\n      (e.g., atazanavir, darunavir, lopinavir, saquinavir, tipranavir,<br \/>\n      cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.g.,<br \/>\n      carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and efavirenz. If<br \/>\n      ZEPATIER is administered with RBV, healthcare professionals should refer<br \/>\n      to the prescribing information for RBV as the contraindications,<br \/>\n      warnings and precautions, adverse reactions and dosing for RBV also<br \/>\n      apply to this combination regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER if ALT levels remain persistently<br \/>\n      greater than 10 times ULN. ZEPATIER should be discontinued if ALT<br \/>\n      elevation is accompanied by signs or symptoms of liver inflammation or<br \/>\n      increasing conjugated bilirubin, alkaline phosphatase, or international<br \/>\n      normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to possible<br \/>\n      clinically significant adverse reactions from greater exposure to<br \/>\n      ZEPATIER or concomitant drugs. Coadministration of ZEPATIER is not<br \/>\n      recommended with certain strong CYP3A inhibitors (e.g., ketoconazole or<br \/>\n      the cobicistat-containing regimens of<br \/>\n      elvitegravir\/cobicistat\/emtricitabine\/tenofovir [disoproxil fumarate or<br \/>\n      alafenamide]). Healthcare professionals should not exceed atorvastatin<br \/>\n      20mg\/daily or rosuvastatin 10mg\/daily when given with ZEPATIER. If<br \/>\n      ZEPATIER is given with fluvastatin, lovastatin or simvastatin,<br \/>\n      healthcare professionals should give the lowest statin dose necessary<br \/>\n      and closely monitor for statin-associated adverse events. If ZEPATIER<br \/>\n      (elbasvir and grazoprevir) and tacrolimus are coadministered, frequent<br \/>\n      monitoring of tacrolimus whole blood concentrations, changes in renal<br \/>\n      function and tacrolimus-associated adverse events is recommended.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER and certain drugs may cause significant<br \/>\n      decrease of elbasvir and grazoprevir plasma concentrations, which may<br \/>\n      lead to reduced therapeutic effect of ZEPATIER and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER is not recommended with<br \/>\n      moderate CYP3A inducers (e.g., nafcillin, bosentan, etravirine,<br \/>\n      modafinil).\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>About ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg Tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, a<br \/>\n      hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3\/4A<br \/>\n      protease inhibitor, and is indicated with or without ribavirin (RBV) for<br \/>\n      treatment of chronic HCV genotype (GT) 1 or GT4 infection in adults. The<br \/>\n      dosing regimens and durations for treatment with once-daily ZEPATIER for<br \/>\n      chronic HCV GT1 or GT4 infection in patients with or without cirrhosis,<br \/>\n      HIV-1 co-infection or renal impairment are as follows:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Twelve weeks of treatment with ZEPATIER is recommended for:<br \/>\n        GT1a-infected patients who are treatment-na\u00efve or who failed prior<br \/>\n        treatment with peginterferon alfa plus RBV (PegIFN\/RBV-experienced)<br \/>\n        without baseline NS5A resistance-associated polymorphisms (amino acid<br \/>\n        positions 28, 30, 31 or 93); GT1b-infected patients who are<br \/>\n        treatment-na\u00efve or PegIFN\/RBV-experienced; and GT4-infected patients<br \/>\n        who are treatment-na\u00efve.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Twelve weeks of&nbsp;treatment with ZEPATIER in combination with RBV is<br \/>\n        recommended for GT1a- or GT1b-infected patients who failed prior<br \/>\n        treatment with PegIFN\/RBV + a HCV NS3\/4A protease inhibitor (PI)<br \/>\n        (boceprevir, simeprevir or telaprevir).&nbsp;For GT1a-infected<br \/>\n        PegIFN\/RBV\/PI-experienced patients with one or more baseline NS5A<br \/>\n        resistance-associated polymorphisms, the optimal ZEPATIER-based<br \/>\n        treatment regimen and duration of therapy has not been established.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Sixteen weeks of treatment with ZEPATIER (elbasvir and grazoprevir) in<br \/>\n        combination with RBV is recommended for: GT1a-infected patients who<br \/>\n        are treatment-na\u00efve or PegIFN\/RBV-experienced with baseline NS5A<br \/>\n        resistance-associated polymorphisms;<sup> <\/sup>and GT4-infected<br \/>\n        patients who are PegIFN\/RBV-experienced.\n      <\/li>\n<\/ul>\n<p>\n      For patients with chronic HCV GT1a infection, testing for the presence<br \/>\n      of NS5A resistance-associated polymorphisms is recommended prior to<br \/>\n      starting treatment with ZEPATIER to determine the optimal dosage regimen<br \/>\n      and duration.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For nearly 30 years, Merck has been at the forefront of the response to<br \/>\n      the HCV epidemic. Merck employees are dedicated to applying their<br \/>\n      scientific expertise, resources and global reach to develop and deliver<br \/>\n      innovative healthcare solutions to support people living with chronic<br \/>\n      HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=fcacf9e6426d6eec4439a7f3f073d525\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=334e8669ec659c9986f7ba338048f51d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=f1f82dba089cdccbba42b67c1925ac0e\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=71f0a6f2bef9f349f74a0c9b9f412c1b\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=35f44258f00d27500fd91ccb27064af2\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=0f6d0fb7c61fa09db77dd394a94a8cd9\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=9&amp;md5=67327af2632f97320bff0b1b7672c76f\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><\/a><b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51318760&amp;newsitemid=20160413005261&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=10&amp;md5=a759154264fb20e6aa47e267f9370362\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><\/a>\n    <\/p>\n<p>\n      ___________________________\n    <\/p>\n<p>\n      <sup>1<\/sup> See Table 2\n    <\/p>\n<p>\n      <sup>2<\/sup> Per the trial protocol, in the FAS all randomized patients<br \/>\n      received at least one (1) dose of study medication. Superiority was<br \/>\n      concluded if the lower bound of the two-sided 95% CI for the difference<br \/>\n      between SVR12 rates in the treatment groups was greater than zero.\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160413005261r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Sarra Herzog,        201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head , the company\u2019s comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN\/RBV) in treatment-na\u00efve and pegIFN\/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection (abstract #PS002). In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN\/RBV, based on pre-specified analyses. In the full analysis set (FAS) (n=255), the efficacy endpoint of sustained virologic response (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) was achieved in 99 percent (128\/129) of patients receiving ZEPATIER for 12 weeks versus 90 percent (114\/126) of patients<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,140,141,64,289],"class_list":["post-745395","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-hepatitis-c","tag-hepatitis-c-newsroom","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head , the company\u2019s comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN\/RBV) in treatment-na\u00efve and pegIFN\/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection (abstract #PS002). In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN\/RBV, based on pre-specified analyses. In the full analysis set (FAS) (n=255), the efficacy endpoint of sustained virologic response (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) was achieved in 99 percent (128\/129) of patients receiving ZEPATIER for 12 weeks versus 90 percent (114\/126) of patients\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\\\/\",\"name\":\"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-04-13T00:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head , the company\u2019s comparative, Phase 3, open-label clinical trial evaluating the efficacy and safety of ZEPATIER\u2122 (elbasvir and grazoprevir) 50mg\/100mg tablets versus a regimen of sofosbuvir 400mg tablets plus peginterferon and ribavirin (pegIFN\/RBV) in treatment-na\u00efve and pegIFN\/RBV treatment-experienced patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infection (abstract #PS002). In this study, ZEPATIER demonstrated superiority on efficacy and safety endpoints compared to sofosbuvir plus pegIFN\/RBV, based on pre-specified analyses. In the full analysis set (FAS) (n=255), the efficacy endpoint of sustained virologic response (SVR) 12 weeks after the completion of therapy (SVR12, considered virologic cure) was achieved in 99 percent (128\/129) of patients receiving ZEPATIER for 12 weeks versus 90 percent (114\/126) of patients","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/","name":"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-04-13T00:00:00+00:00","dateModified":"2025-11-07T06:25:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-zepatier-elbasvir-and-grazoprevir-showed-superiority-on-efficacy-and-safety-endpoints-compared-to-sofosbuvir-plus-peginterferon-and-ribavirin-treatment-regimen-in-phase-3-tr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s ZEPATIER\u2122 (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"13ef1daf-29bb-4278-8050-5b5e874fdf64","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-ZEPATIER-Elbasvir-and-Grazoprevir-Showed-Superiority-on-Efficacy-and-Safety-Endpoints-Compared-to-Sofosbuvir-Plus-Peginterfero-YZDO7.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745395\/revisions"}],"predecessor-version":[{"id":3674789,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745395\/revisions\/3674789"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745395"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}